The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report

被引：7
|
作者：
Zang, Jing [1 ,2 ]
Horinouchi, Hidehito [3 ]
Hanaoka, Jun [4 ]
Funai, Kazuhito [5 ]
Sakakura, Noriaki [6 ]
Liao, Hu [7 ]
机构：
[1] Sichuan Univ, West China Univ Hosp 2, Dept Ultrasound, West China Womens & Childrens Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Peoples R China
[3] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo, Japan
[4] Shiga Univ Med Sci, Dept Surg, Div Gen Thorac Surg, Otsu, Shiga, Japan
[5] Hamamatsu Univ Sch Med, Dept Surg 1, Higashi Ku, Hamamatsu, Shizuoka, Japan
[6] Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi, Japan
[7] Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC DISEASE | 2021年 / 13卷 / 07期
关键词：
RECEPTOR EGFR MUTATION; OPEN-LABEL; 1ST-LINE ERLOTINIB; CHEMOTHERAPY; MULTICENTER; AFATINIB;
D O I：
10.21037/jtd-21-171
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：4554 / 4559
页数：6
相关论文
共 50 条
  • [21] Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
    Sudo, Makoto
    Mori, Seiichi
    Madan, Vikas
    Yang, Henry
    Leong, Geraldine
    Koeffler, H. Phillip
    ONCOTARGET, 2015, 6 (02) : 814 - 824
  • [22] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [23] Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
    Bae, Song Yi
    Hong, Ji-Young
    Lee, Hye-Jung
    Park, Hyen Joo
    Lee, Sang Kook
    ONCOTARGET, 2015, 6 (12) : 10146 - 10160
  • [24] Antitumor Impact of p14ARF on Gefitinib-Resistant Non-Small Cell Lung Cancers
    Saito, Ken
    Takigawa, Nagio
    Ohtani, Naoko
    Iioka, Hidekazu
    Tomita, Yuki
    Ueda, Ryuzo
    Fukuoka, Junya
    Kuwahara, Kazuhiko
    Ichihara, Eiki
    Kiura, Katsuyuki
    Kondo, Eisaku
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (08) : 1616 - 1628
  • [25] Erlotinib/gefitinib/osimertinibDevelopment of resistance in non-small cell lung cancer: case report
    Reactions Weekly, 2021, 1850 (1) : 131 - 131
  • [26] Gefitinib/osimertinibAcquired resistance in advanced non-small cell lung cancer: case report
    Reactions Weekly, 2021, 1863 (1) : 165 - 165
  • [27] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
    Song Zheng-bo
    Yu Yong-feng
    Chen Zhi-wei
    Lu Shun
    CHINESE MEDICAL JOURNAL, 2011, 124 (15) : 2279 - 2283
  • [28] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [29] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
    SONG ZhengboYU YongfengCHEN Zhiwei and LU Shun Shanghai Lung Tumor Clinical Medical CenterChest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
    中华医学杂志(英文版), 2011, (15) : 2279 - 2283
  • [30] Chemical Synthesis of Novel DDR1 Inhibitors and Their Activity Against Gefitinib-Resistant Non-Small Cell Lung Cancer
    Xuemei Xu
    Siyu Chen
    Doudou Sun
    Xuebao Wang
    Zhouyang Xu
    Russian Journal of Bioorganic Chemistry, 2025, 51 (1) : 285 - 297
12345